QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module VII: PSUR Assessment, PRAC and Regulatory Follow-Up Knowledge Assessment

Test your understanding of the concepts covered by GVP Module VII: PSUR Assessment, PRAC and Regulatory Follow-Up.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An organisation records only 'variation required' in its action tracker and does not review the assessment report. What important risk does this create?

It may miss scientific uncertainties, future PSUR requests, RMP implications and additional monitoring expectations It prevents PRAC from adopting any recommendation It automatically invalidates the submitted PSUR It ensures that all affected products receive identical implementation

Question 2 of 10 Which completion criterion is most defensible for a PSUSA-related implementation action?

The responsible employee believes the task is complete The submission was sent to the authority The required regulatory outcome has been implemented as applicable, verified across affected systems or products and supported by retained evidence The procedure has been removed from the active tracker

Question 3 of 10 A company's product contains the same active substance as products included in a PSUSA, but the company's product is outside that PSUSA scope. What is the most appropriate action?

Automatically implement the PSUSA recommendation without further assessment Ignore the recommendation because the product was not formally included Assess the scientific relevance to the product and determine the appropriate regulatory action; automatic application should not be assumed Apply the recommendation only if another company has already done so

Question 4 of 10 Why must a PSUSA outcome be mapped separately to CAPs and NAPs when an organisation has both types of products?

CAPs and NAPs always have different active substances The authorisation status can determine the applicable downstream regulatory and implementation pathway NAPs are outside pharmacovigilance requirements after a PSUSA CAPs cannot be affected by product-information changes

Question 5 of 10 Which statement best describes the relationship between PSUSA assessment and signal management?

They are mutually exclusive processes, so a signal cannot be managed during a PSUSA PSUSA replaces signal management for the reporting interval They are complementary; signals may inform the PSUR and PSUSA conclusions should feed back into ongoing signal management Signal management is relevant only after a Commission decision

Question 6 of 10 What is the correct interpretation of a PRAC recommendation to maintain the marketing authorisation in the applicable procedure?

No safety information was identified and routine pharmacovigilance can stop The regulatory conclusion is that maintenance is appropriate, although continuing monitoring or follow-up may still be required The recommendation is automatically a Commission decision for all products The MAH is prohibited from considering the outcome in future PSURs

Question 7 of 10 Why is procedure closure not necessarily the same as pharmacovigilance action closure?

Regulatory procedures can never be formally closed Publication of an outcome may create continuing obligations such as variations, studies, risk minimisation or future reporting MAHs are required to keep every procedure open indefinitely Only the QPPV can close a regulatory procedure

Question 8 of 10 How should an important new safety concern arising during implementation of an earlier PSUSA action be managed?

Assume it is automatically covered by the existing PSUSA action Ignore it until the next periodic report Assess it through applicable ongoing signal-management and regulatory processes while keeping it separately traceable from the earlier action Close the earlier action and combine all records into one undifferentiated issue

Question 9 of 10 What is the principal reason that PSUR assessment is treated as a separate activity from PSUR preparation?

The regulator independently evaluates the cumulative evidence and may reach a different conclusion from the MAH The MAH is not responsible for evaluating any safety information in the PSUR Technical validation automatically confirms the scientific conclusions in the PSUR The assessment is limited to checking whether the PSUR follows the required document format

Question 10 of 10 Why may identical active-substance products require different product-information impact assessments?

Each product must have unrelated safety information Products may differ in indications, populations, authorised wording and regulatory history Product information is never relevant to PSUSA implementation Only centrally authorised products have product information

QPPV.com

GVP Module VII: PSUR Assessment, PRAC and Regulatory Follow-Up Knowledge Assessment

Cookie Settings